Q3 2025 revenue of €143.1 million for YORVIPATH® and €50.7 million for SKYTROFA® – Q3 2025 operating profit of €11.0 million – TransCon® CNP (navepegritide) under FDA Priority Review for the treatment ...
Nordic stocks gained Wednesday, with the OMX Nordic 40 Index rising 1.1%. Olav Thon Eiendomsselskap ASA was the biggest leader among large stocks during the session, soaring 22.1%, and Munters Group ...
The Calamos Global Opportunities Fund returned 6.42%, capturing a majority of the 7.74% return of the MSCI ACWI Index and ...
Zealand Pharma A/S was the biggest leader among large stocks during the session, adding 8.7%, and Novo Nordisk A/S rose 6.4%. Vimian Group AB rounded out the top three leaders on Tuesday, with shares ...
Q3 2025 review for the. See how overweight tech positions drove outperformance and explore our bullish outlook on Europe & ...
Newspoint on MSN
If you earn ₹100,000 in Denmark, how much will you earn in India? Find out how strong its currency is.
This country is known not only for its clean roads, modern lifestyle, and prosperous environment, but its salary scale also ...
The most active issuer in the Nordic currencies remains NIB, which sold nine trades in each of Nokkie and Sekkie, including ...
Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards. COPENHAGEN, Denmark – ...
Novo Nordisk Q3 profit drops on restructuring costs as GLP-1 and obesity drug sales rise; company narrows 2025 growth outlook ...
Novo Nordisk lowers its 2025 profit forecast as new CEO Mike Doustdar faces rising competition, leadership changes, and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback